ArticleKidney3602026
Length of Follow-Up Time Needed for Stable eGFR Slope Estimation in Glomerular Disease.
Article in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
key pointsSeveral years of follow-up are necessary to accurately estimate long-term eGFR slopes in patients with glomerular disease. Moderately sized gaps between eGFR measurements are acceptable when estimating long-term eGFR slopes.
backgroundSlope of eGFR is an important measurement of kidney disease progression and clinical outcome in glomerular disease. However, the length of time required to reliably estimate long-term eGFR slopes is unknown. Furthermore, the impact of missing data on eGFR slope estimation is unclear.
methodsData from the Cure Glomerulonephropathy (CureGN) study were used to answer two questions. A Total Duration question compared eGFR slope estimates based on shorter intervals of follow-up (FU) with true long-term slopes using descriptive statistics, overall and within patient subgroups based on age, disease diagnosis, disease activity at study enrollment and during FU, nonlinearity of the eGFR trajectory, and eGFR measurement frequency. A Duration after Missingness question simulated missing data to examine different lengths of FU time after initial gaps between biopsy and study enrollment to compare eGFR slope estimates with true complete-data eGFR slopes, overall and within patient subgroups.
resultsFor the Total Duration question, eGFR slope estimates gradually became more accurate with longer FU, with 86% of slopes based on 3.5-4 years of FU within 5 ml/min per 1.73 m 2 per year of true long-term slopes. For the Duration after Missingness question, 84% of eGFR slopes based on over 2 years of FU were within 5 ml/min per 1.73 m 2 per year of true complete-data slopes after initial missing data gaps between 6 and 24 months. For both questions, eGFR slopes stabilized faster for adults compared with children and for those diagnosed with membranous nephropathy or IgA nephropathy compared with minimal change disease or FSGS. For the Total Duration question, participants with nonlinear trajectories required much longer time to achieve stable eGFR slopes compared with those with linear trajectories.
conclusionsSeveral years of FU are necessary to accurately estimate long-term eGFR slopes in patients with glomerular disease, but moderately sized gaps between eGFR measurements are acceptable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.